TPIAO®

Thrombopoietin (TPO) is an endogenous cytokine which can stimulate the growth and differentiation of megakaryocyte. It can increase the quantity of platelet through its stimulative function on each growth phase of megalokaryocyte including proliferation of pro-cell, development and maturation of polyploidy megalokaryocyte. Recombinant human thrombopoietin(rhTPO)is a full-length glycosylated thrombopoietin which is expressed in China Hamster Ovary (CHO) cell line via recombinant genetic technology. It has similar pharmacological function on increasing the quantity of platelet with endogenous thrombopoietin.

Indication :

TPIAO is suitable for the thrombocytopenia associated with chemotherapy in cancer patients with solid tumours. TPIAO therapy is recommended to patients with the platelet level lower than 50×109/L or physicians considered it necessary to increase the level of plateletTPIAO is developed by Sunshine itself as National Class I New Drug, which is the first recombinant human thrombopoietin approved launched on the market all over the world. rhTPO is considered to another landmark of biopharmaceuticals after rhEPO and rhG/GM-CSF.

In 2011, the SFDA approved TPIAO for the treatment of immune thrombocytopenia (ITP).